If confirmed, therapeutic consideration should be given to inhibiting both IL-6 and GC activity in most of the patients with COVID-19 exhibiting this phenotype (high IL-6, low IFN signaling, and profound cytopenias) versus the small proportion of patients with a true cytokine storm phenotype. Here, IL6 is linked to COVID-19.